MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints

/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the...

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Boston ,Massachusetts ,United States ,Jon Monson ,Steve Bailey ,Reinoud Knops ,Kenneth Stein ,Heart Rhythm Society ,Twitter ,Exchange Commission ,Boston Scientific ,Linkedin ,Drug Administration ,Prnewswire Boston Scientific Corporation ,Boston Scientific Corporation ,Department Of Cardiology ,Securities Exchange ,Subcutaneous Implantable Defibrillator ,Scientific Corporation ,Leadless Pacemaker ,Heart Rhythm ,New England Journal ,European Economic ,Securities Act ,Securities Exchange Act ,Risk Factors ,Annual Report ,Quarterly Reports ,